[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients]
- PMID: 20585185
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients]
Abstract
Cardiovascular complications due to accelerated atherosclerosis and arterial stiffening are the principal cause of morbidity and mortality in patients with dialysis. Both are frequently associated with vascular calcification. Uremia-specific factors are considered to play an important role in promoting these aortic wall changes, and may be more important than classical atherogenic risk factors. Disorders of calcium and phosphorus metabolism and secondary hyperparathyroidism have been recognized as independent risk factors of bone disease, and also soft tissue calcification, including arterial calcification and atheroma. The best strategy to treat, or even prevent, this complication would consist of control of serum phosphate concentration.
Similar articles
-
[CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder].Clin Calcium. 2010 Jul;20(7):995-1003. Clin Calcium. 2010. PMID: 20585177 Review. Japanese.
-
[Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].Clin Calcium. 2007 Dec;17(12):1870-8. Clin Calcium. 2007. PMID: 18057663 Review. Japanese.
-
[Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].Clin Calcium. 2009 Apr;19(4):493-9. Clin Calcium. 2009. PMID: 19329827 Review. Japanese.
-
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Bone metabolism in CKD-MBD].Clin Calcium. 2010 Jul;20(7):1038-44. Clin Calcium. 2010. PMID: 20585182 Review. Japanese.
-
[Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].Clin Calcium. 2007 Mar;17(3):354-9. Clin Calcium. 2007. PMID: 17339739 Review. Japanese.
Cited by
-
Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.Biomed Res Int. 2013;2013:320560. doi: 10.1155/2013/320560. Epub 2012 Dec 27. Biomed Res Int. 2013. PMID: 23509710 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical